ORIC Pharmaceuticals, Inc.

NASDAQ: ORIC · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001796280Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 66DQ —GM —SS 59

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$129.5M

Employees

111

as of 2026-08-10

Market cap

$1.4B

as of 2026-08-10

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$129.5M-$129.5M2025

Operating income-$143.0M-$143.0M2025

Total assets$408.9M$408.9M2025

Liabilities$24.5M$24.5M2025

Equity$384.4M$384.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is ORIC Pharmaceuticals, Inc.’s financial profile?

ORIC Pharmaceuticals, Inc. earned -$129.5M in FY2025 net income.

Peers · Healthcare

Bicara Therapeutics Inc. Common Stock——First Tracks Biotherapeutics Inc——ArriVent BioPharma, Inc.——LB Pharmaceuticals Inc Common Stock——Avalyn Pharma Inc. Common Stock——Vor Biopharma Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEOJacob Chacko

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: ORIC

Employees111

IPO date2020-04-24

Latest filings

10-Q2026-08-03 8-K2026-08-03 8-K2026-07-30 8-K2026-06-22 8-K2026-05-04 10-Q2026-05-04 DEF 14A2026-04-28 8-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.